**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74260

**Manuscript Type:** CASE REPORT

**MutL homolog 1germline mutation c.(453+1\_454-1)\_(545+1\_546-1)del identified in lynch syndrome: A case report and review of literature**

Zhang XW *et al*. *MLH1* germline mutation identified in LS

Xi-Wen Zhang, Zan-Hui Jia, Li-Ping Zhao, Yi-Shi Wu, Man-Hua Cui, Yan Jia, Tian-Min Xu

**Xi-Wen Zhang, Zan-Hui Jia, Li-Ping Zhao, Yi-Shi Wu, Man-Hua Cui, Yan Jia, Tian-Min Xu,** Department of Gynecology, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China

**Author contributions:** Zhang XW, Jia ZH, and Zhao LP were the patient’s gynecologic surgeons, reviewed the literature, and contributed to manuscript drafting; Wu YS, Xu TM, and Jia Y were responsible for the revision of the manuscript for important intellectual content; Cui MH analyzed and interpreted the imaging findings; all authors issued final approval for the version to be submitted.

**Supported by** the Natural Science Fund of Science and Technology Department, Jilin, No. 20180101010JC; Jilin Provincial Department of Education, No. JJKH20201049KJ.

**Corresponding author: Man-Hua Cui, MD, PhD, Chief Doctor,** Department of Gynecology, The Second Hospital of Jilin University, No. 218 Ziqiang Road, Changchun 130000, Jilin Province, China. cuimh@jlu.edu.cn

**Received:** December 18, 2021

**Revised:** February 4, 2022

**Accepted:** **May 27, 2022**

**Published online:**

**Abstract**

BACKGROUND

Lynch syndrome (LS) is an autosomal dominant hereditary disorder because of germline mutations in DNA mismatch repair genes, such as MutL homolog 1 (*MLH1*), PMS1 homolog 2, MutS homolog 2, and MutS homolog 6. Gene mutations could make individuals and their families more susceptible to experiencing various malignant tumors. In Chinese, *MLH1* germline mutation c.(453+1\_454-1)\_(545+1\_546-1)del-related LS has been infrequently reported. Therefore, we report a rare LS patient with colorectal and endometrioid adenocarcinoma and describe her pedigree characteristics.

CASE SUMMARY

A 57-year-old female patient complained of irregular postmenopausal vaginal bleeding for 6 mo. She was diagnosed with LS, colonic malignancy, endometrioid adenocarcinoma, secondary fallopian tube malignancy, and intermyometrial leiomyomas. Then, she was treated by abdominal hysterectomy, bilateral oviduct oophorectomy, and sentinel lymph node resection. Genetic testing was performed using next-generation sequencing technology to detect the causative genetic mutations. Moreover, all her family members were offered a free genetic test, but no one accepted it.

CONCLUSION

No tumor relapse or metastasis was found in the patient during the 30-mo follow-up period. The genetic panel sequencing showed a novel pathogenic germline mutation in *MLH1*, c.(453+1\_454-1)\_(545+1\_546-1)del, for LS. Moreover, cancer genetic counseling and testing are still in the initial development state in China, and maybe face numerous challenges in the further.

**Key Words:** Lynch syndrome; Colorectal cancer; Endometrial cancer; *MLH1* gene; Gene testing; Case report

Zhang XW, Jia ZH, Zhao LP, Wu YS, Cui MH, Jia Y, Xu TM. MutL homolog 1 germline mutation c.(453+1\_454-1)\_(545+1\_546-1)del identified in lynch syndrome: A case report and review of literature. *World J Clin Cases* 2022; In press

**Core Tip:** Lynch syndrome (LS) is an autosomal dominant hereditary disorder because of germline mutations in DNA mismatch repair genes, such as MutL homolog 1 (*MLH1*) gene, PMS1 homolog 2 gene, MutS homolog 2 gene, andMutS homolog 6 gene, which make the patient more susceptible to other malignancies. In Chinese, *MLH1* germline mutation c.(453+1\_454-1)\_(545+1\_546-1)del-induced LS has been infrequently reported. In this paper, we report a rare LS patient with colorectal and endometrioid adenocarcinoma. The genetic panel sequencing showed a novel pathogenic germline mutation in *MLH1,* c.(453+1\_454-1)\_(545+1\_546-1)del, for LS.

**INTRODUCTION**

Lynch syndrome (LS) is an autosomal dominant inherited disorder because of germline mutations in DNA mismatch repair (*MMR*) genes, such as MutL homolog 1 (*MLH1*), PMS1 homolog 2 (*PMS2*), MutS homolog 2 (*MSH2*), and MutS homolog 6 (*MSH6*), which make the patient more susceptible to other malignancies[1,2]. *MLH1*, *MSH2*, *MSH6*, and *PMS2* mutations in LS account for approximately 50%[3-5], 40%[5], 7%-20%[3-8], and < 6%[3,4,9] of all cases, respectively. Additionally, specific *MMR* gene deficiencies might result in different ages of onset, types of malignancy, and clinical signs[10]. The *MLH1* gene defects could decrease the expression of *MLH1* protein, affecting the MMR function, leading to errors in DNA replication and ultimately inducing neoplams[11,12].

LS can be classified as types I and II according to the location of tumors[3,13,14]. Type I is an intestinal neoplasm, such as colorectal cancer[14]. Besides, type II is defined as colorectal malignancy complicated with parenteral cancers, including gastric cancer[15], renal cell cancer[16], epithelial ovarian cancer[17], endometrial cancer[2], bladder cancer[18,19], breast cancer[20], and even repeated stroke[10]. Endometrial cancer is the most frequent parenteral tumor among LS patients[21,22], which ranks 3rd in the mortality of all gynecological cancers[23]. In recent years, LS-associated endometrial cancer (LSAEC) has received increasing attention in the medical field[24]. Furthermore, the offspring of LS patients will have a 50% incidence of inheritance[24]. More than 2600 mutations have been reported worldwide[10,24,25], but *MLH1* exon 6 c.(453+1\_454-1)\_(545+1\_546-1)del-induced LS has been rarely described in Chinese. Therefore, we present a rare case with an *MLH1* germline mutation, analyze her pedigree characteristics, and review the *MLH1* gene mutation loci.

**CASE PRESENTATION**

***Chief complaints***

A 57-year-old Chinese female patient complained of irregular postmenopausal vaginal bleeding. The demographic characteristics of the patient are listed in Table 1.

***History of present illness***

The patient had the clinical symptom of irregular vaginal bleeding for 6 mo.

***History of past illness***

The patient had a medical history of colon cancer and received a radical colon cancer operation 20 years ago.

***Personal and family history***

The patient and many of her family members had a cancer history.

***Physical examination***

A small amount of white secretions with no odor was found in the vagina. A smooth cervical surface was detected. The vulva was atrophic, the vagina was patent, and mucosal fold atrophy was palpated. Moreover, the uterine was in an anterior position, with a smooth surface and good range of motion. No obvious abnormality was found in the bilateral adnexal areas.

***Laboratory examinations***

No abnormality was found in the routine blood tests.

***Imaging examinations***

***Ultrasound***

Preoperative abdominal Doppler ultrasound showed that the uterus, with a size of 3.8 cm × 3.5 cm × 3.1 cm, was located in an anterior position, the uterine cavity line was clear, the endometrial thickness was 1.1 cm (significantly greater than the normal value of endometrial thickness in postmenopausal women), and the ultrasonic echo of the endometrium was uneven. In addition, bilateral ovaries and adnexa presented no abnormality. Color Doppler flow imaging showed no abnormal blood flow signal.

***Magnetic resonance imaging***

Abdominal magnetic resonance imaging showed that the uterus was in an anteversion and flexion position. A mass with an equal T1 and slightly long T2 signal was found in the uterine cavity, with an unclear boundary (Figure 1A). The tumor size was about 31 mm × 23 mm, and the display of the uterine junction was not clear (Figure 1B and C). The enhanced images showed that the lesions exhibited inhomogeneous enhancement. Diffusion-weighted imaging showed that the lesions exhibited a high signal. The shape and signal of the bilateral adnexa were normal (Figure 1D). There was no obvious abnormal signal in the bladder and rectum. No abnormality was found in bilateral iliac vessels and inguinal lymph nodes. No effusion was found in the pelvic cavity, and no obvious abnormal signal was found in pelvic wall soft tissue.

**FINAL DIAGNOSIS**

The clinical diagnosis was endometrioid adenocarcinoma (IIIA1) and LS.

**TREATMENT**

After general anesthesia, abdominal hysterectomy and bilateral oviduct oophorectomy were performed. The whole uterus and bilateral appendages were examined during the operation by fast-frozen histopathology. It revealed a poorly differentiated adenocarcinoma of the uterus, which infiltrated the superficial muscularis. Subsequently, sentinel lymph node resection was also performed. After surgery, the patient was treated with regular chemotherapy for six courses, including paclitaxel (Nanjing Green Leaf Pharmaceutical Co., Ltd., Nanjing, China) and carboplatin injection (Qilu Pharmaceutical Co., Ltd., Jinan, China).

**OUTCOME AND FOLLOW-UP**

The biopsy histochemical (hematoxylin-eosin) staining showed that endometrial cancer was moderately to poorly differentiated. A few of its lesions were accompanied by squamous differentiation. The tumor infiltrated into the superficial muscle wall. Noticeably, one side of the fallopian tube showed cancerous lesions, while the other side of the fallopian tube and bilateral ovaries showed no cancerous lesions. However, cervical vessels, blood vessels, lymphatic vessels, and nerves were not invaded. Bilateral pelvic lymph nodes were normal.

Immunohistochemical (IHC) staining results showed MLH1 (-), PMS2 (-), MSH6 (+-), MSH2 (+-), BRAF V600E mutation-specific antibody (VE1) (Ventana IHC enhanced amplification kit) (-), CD31 (-), D2-40 (-), CK5/6 (partial lesions +-), p63 (+-), and CDX2 (-) (Figure 2). Besides, the positive rate of PR was 90+ACU- (+-). The positive rate of ER was 90+ACU- (+-). The positive rate of Ki67 was 60+ACU-. P53 was scattered weak positive, and P16 was partially positive. Based on these findings, the patient was diagnosed with endometrioid adenocarcinoma (IIIA1).

No tumor recurrence or metastasis was found during a 2.5-year follow-up period. Computed tomography was performed after six chemotherapy courses and showed no abnormality in the head, liver, gallbladder, spleen, pancreas, bilateral kidney, bilateral ureter, rectum, or lung.

The results of gene sequencing are shown in Tables 2 and 3. A heterozygous deletion mutation of exon 6 was detected in the *MLH1* gene, which was named c.(453+-1+AF8-454-1)+AF8-(545+-1+AF8-546-1)del according to the Human Genome Variation Society (Figure 3). Postoperatively, the patient was diagnosed with LS, endometrioid adenocarcinoma (IIIA1), colonic malignancy, secondary fallopian tube malignancy, and intermyometrial leiomyomas.

The patient’s eldest sister was diagnosed with colon cancer at age 60, the second sister with endometrial cancer at age 60, the third sister with colon cancer at age 40, the older brother with colon polyps three times between the ages of 40 and 50, the mother with endometrial cancer at age 48, and the mother with colon cancer at age 50. The prevalence spectrum of the four generations of patients is shown in Figure 4.

Genetic counseling was conducted among the family relatives. Moreover, we provided free Sanger mutation site verification tests for the family members of the patient. However, all relatives refused to be tested.

**DISCUSSION**

Colorectal cancer is the 5th commonly diagnosed cancer in China[23,26]. In 2015, the number of colorectal cancer-related deaths and new cases in China was approximately 191000 and 376300, respectively. Moreover, hereditary colorectal malignancy accounts for 5%-10% of colorectal malignancies, including LS, Li-Fraumeni syndrome, MUTYH-associated polyposis, juvenile polyposis syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome[27]. In this study, the patient had a medical history of colon cancer 20 years ago and has experienced endometrial adenocarcinoma. We found that the patient carries a novel pathogenic genetic deletion mutation in *MLH1*. Many researchers have reported diseases caused by *MLH1* gene mutations[28-31]. Hong *et al*[31] detected that the deletion of exon 7 to exon 19 of the *MLH1* gene was a pathogenic mutation causing colorectal cancer. Jia *et al*[28] reported that the p.K618del variant in *MLH1* was the causative pathogenic genetic variant for LS. Solassol *et al*[29] found that an *AluY5a* insertion in *MLH1* exon 6 led to exon skipping, which resulted in a pathogenic frameshift in patients who developed colorectal adenocarcinomas. Li *et al*[30] reported that the insertion of a truncated *AluSx* like element into *MLH1* intron 7 resulted in aberrant splicing and transcription, thus inducing LS. Lagerstedt-Robinson *et al*[32] reported an LS patient with the deletion of *MLH1* c.(453+1\_454-1)\_(545+1\_546-1) in Switzerland. However, in China, the *MLH1*genetic mutation c.(453+1\_454-1)\_(545+1\_546-1) del has not been reported. Consequently, we present a relatively rare LS patient with *MLH1* c.(453+1\_454-1)\_(545+1\_546-1)del and describe the clinical features, pathological features, and familial morbidity of the proband.

The demographic characteristics of LSAEC are as follows: First, the pathological types are diverse and poorly differentiated. Second, the onset age is between 46 and 54 years old. Third, the majority of the pathological changes are situated in the lower segment of the corpus uteri[33]. The potential risk of LS patients experiencing another cancer at 10 and 15 years was 25% and 50%, respectively[34]. The present case had colon cancer at age 37. Twenty years later, she was diagnosed with endometrioid adenocarcinoma. The demographic characteristics of the present patient were similar to those reported in the previous studies[21,34].

Concerning the diagnosis of LS, Amsterdam II[35] and Bethesda[36] criteria have been widely used to screen for LS. In the present study, the patient met the criteria of the Amsterdam standard Ⅱ and the revision of the Bethesda guidelines. Nonetheless, the two standards’ sensitivity is low because they are based on clinical background and family history[37-39]. Thus, Amsterdam II and Bethesda criteria are inadequate as independent screening tools.

IHC was a useful method for LS screening[37,40,41], particularly in colorectal malignancy patients. The sensitivity and specificity of IHC in patients with MMR mutations are 83% and 89%, respectively[42]. When IHC results suggest deleting *MLH1* and *PMS2* proteins, universal screening including *BRAF* testing and *MLH1* promoter methylation analysis is required[10,22,24,25,28,38-40,43,44]. In the present study, the IHC results showed the loss of *MLH1* and *PMS2* proteins, but expression of *MSH2* and *MSH6* proteins in the tumor cells. Subsequently, *MLH1* mutation was considered. The patient had a medical history of colon cancer and a family history of LS-related cancers. Then, she was diagnosed with LS. Also, we advised the patient and her family members to receive genetic counseling.

Before genetic testing, we provided genetic counseling for the patient and obtained a clear LS family history. We found that the proband’s mother (I-1) suffered from primary colon cancer at 55 years and died at 70 years, two of her sisters [(II-1) and (II-3)] were affected by colon cancer at 60 years and endometrial cancer at 60 years, respectively, one of her sisters (II-5) experienced colon cancer at 40 years and endometrial cancer at 48 years, her brother (II-7) developed polyps of the colon, and her nephew developed colon cancer at 25 years and died at 27 years. Besides, standard processes of cancer-related genetic counseling should include pre-test counseling, results analysis, and follow-up[28]. In our study, the family history suggested the clinical diagnosis of LS. Then, the patient and family members were given detailed pre-test counseling. However, we cannot make a definitive diagnosis of LS without genetic testing[28]. Consequently, genetic testing was recommended for the proband and her relatives.

Furthermore, we provided free genetic tests for all her family members to help at-risk offspring know their risk of developing cancers, thus enabling them to access personalized precision medicine. Unexpectedly, only the proband received the genetic test, but her family members refused. The reasons for the relatives of the proband to refuse genetic testing are as follows: First, they were worried that their genetic problems may cause difficulties in mate selection or affect the stability of marriage. Second, they will be unable to purchase life insurance if they have a genetic defect. Third, they are worried about personal privacy exposure. Wang *et al*[45] investigated the willingness and awareness of genetic screening for patients undergoing colon cancer surgery at Peking Union Medical College Hospital who had any protein (*MLH1/MLH2/MLH6/PMS2*) expression deletion suggested by IHC, and the result indicated that 27.4% (61/219) of the patients explicitly refused to undergo genetic screening. The findings of our study and Wang *et al*[45] indicate that gynecologists should strengthen health education. Therefore, cancer genetic counseling and testing are still in the initial development stage in China, and maybe face numerous challenges in the further[28]. This dilemma is expected to be improved with better preventative education to the general population and a better understanding of cancer genetics among cancer patients and medical practitioners[28].

The patient achieved positive clinical outcomes during the 30-mo follow-up visit period. However, several limitations exist in this study. First, 6 mo after discharge, the proband’s 25-year-old offspring (III-4) was diagnosed with colon cancer and died at age 27. We believe that this unfortunate outcome could have been prevented if her family members had taken genetic testing and then received individualized preventive treatment before the malignant tumor onset. Thus, it is essential to enhance genetic testing awareness among the Chinese population, especially in rural areas.

**CONCLUSION**

*MLH1* exon 6 c.(453+1\_454-1)\_(545+1\_546-1)del mutation is a novel pathogenic mutation of LS in Chinese. This case report emphasizes the value of diagnosis and treatment in patients with inherited malignancy syndromes. To date, cancer genetic counseling and testing are still in the initial development state in China, and maybe face numerous challenges in the further.

**REFERENCES**

1 **Kahn RM,** Gordhandas S, Maddy BP, Baltich Nelson B, Askin G, Christos PJ, Caputo TA, Chapman-Davis E, Holcomb K, Frey MK. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? *Cancer* 2019; **125**: 3172-3183 [PMID: 31150123 DOI: 10.1002/cncr.32203]

2 **Ryan NAJ,** Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. *Genet Med* 2019; **21**: 2167-2180 [PMID: 31086306 DOI: 10.1038/s41436-019-0536-8]

3 **Bhattacharya P,** McHugh TW. Lynch Syndrome. StatPearls. Treasure Island (FL), 2019 [DOI: 10.5040/9780571352654.00000004]

4 **Borràs E**, Pineda M, Cadiñanos J, Del Valle J, Brieger A, Hinrichsen I, Cabanillas R, Navarro M, Brunet J, Sanjuan X, Musulen E, van der Klift H, Lázaro C, Plotz G, Blanco I, Capellá G. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. *J Med Genet* 2013; **50**: 552-563 [PMID: 23709753 DOI: 10.1136/jmedgenet-2012-101511]

5 **Peltomäki P**. Role of DNA mismatch repair defects in the pathogenesis of human cancer. *J Clin Oncol* 2003; **21**: 1174-1179 [PMID: 12637487 DOI: 10.1200/JCO.2003.04.060]

6 **Miyaki M**, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet* 1997; **17**: 271-272 [PMID: 9354786 DOI: 10.1038/ng1197-271]

7 **Berends MJ**, Wu Y, Sijmons RH, Mensink RG, van der Sluis T, Hordijk-Hos JM, de Vries EG, Hollema H, Karrenbeld A, Buys CH, van der Zee AG, Hofstra RM, Kleibeuker JH. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. *Am J Hum Genet* 2002; **70**: 26-37 [PMID: 11709755 DOI: 10.1086/337944]

8 **Nilbert M**, Wikman FP, Hansen TV, Krarup HB, Orntoft TF, Nielsen FC, Sunde L, Gerdes AM, Cruger D, Timshel S, Bisgaard ML, Bernstein I, Okkels H. Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. *Fam Cancer* 2009; **8**: 75-83 [PMID: 18566915 DOI: 10.1007/s10689-008-9199-3]

9 **Senter L**, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, Lindblom A, Lagerstedt K, Thibodeau SN, Lindor NM, Young J, Winship I, Dowty JG, White DM, Hopper JL, Baglietto L, Jenkins MA, de la Chapelle A. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* 2008; **135**: 419-428 [PMID: 18602922 DOI: 10.1053/j.gastro.2008.04.026]

10 **Zhang M,** Yang H, Chen Z, Fan Y, Hu X, Liu W. Lynch syndrome-associated repeated stroke with MLH1 frame-shift mutation. *Neurol Sci* 2021; **42**: 1641 [PMID: 33528673 DOI: 10.1007/s10072-021-05098-1]

11 **Ahadova A**, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, Stenzinger A, Burn J, von Knebel Doeberitz M, Bläker H, Kloor M. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. *Int J Cancer* 2018; **143**: 139-150 [PMID: 29424427 DOI: 10.1002/ijc.31300]

12 **Menahem B**, Alves A, Regimbeau JM, Sabbagh C. Lynch Syndrome: Current management In 2019. *J Visc Surg* 2019; **156**: 507-514 [PMID: 31445799 DOI: 10.1016/j.jviscsurg.2019.07.009]

13 Vasen HFA. Progress Report: New insights into the prevention of CRC by colonoscopic surveillance in Lynch syndrome. *Fam Cancer* 2022; **21**: 49-56 [PMID: 33464460 DOI: 10.1007/s10689-020-00225-x]

14 **Ahadova A**, Seppälä TT, Engel C, Gallon R, Burn J, Holinski-Feder E, Steinke-Lange V, Möslein G, Nielsen M, Ten Broeke SW, Laghi L, Dominguez-Valentin M, Capella G, Macrae F, Scott R, Hüneburg R, Nattermann J, Hoffmeister M, Brenner H, Bläker H, von Knebel Doeberitz M, Sampson JR, Vasen H, Mecklin JP, Møller P, Kloor M. The "unnatural" history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. *Int J Cancer* 2021; **148**: 800-811 [PMID: 32683684 DOI: 10.1002/ijc.33224]

15 **Ladigan-Badura S**, Vangala DB, Engel C, Bucksch K, Hueneburg R, Perne C, Nattermann J, Steinke-Lange V, Rahner N, Schackert HK, Weitz J, Kloor M, Kuhlkamp J, Nguyen HP, Moeslein G, Strassburg C, Morak M, Holinski-Feder E, Buettner R, Aretz S, Loeffler M, Schmiegel W, Pox C, Schulmann K; German Consortium for Familial Intestinal Cancer. Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. *Int J Cancer* 2021; **148**: 106-114 [PMID: 32930401 DOI: 10.1002/ijc.33294]

16 **Therkildsen C**, Joost P, Lindberg LJ, Ladelund S, Smith-Hansen L, Nilbert M. Renal cell cancer linked to Lynch syndrome: Increased incidence and loss of mismatch repair protein expression. *Int J Urol* 2016; **23**: 528-529 [PMID: 27168032 DOI: 10.1111/iju.13094]

17 **Ketabi Z**, Bartuma K, Bernstein I, Malander S, Grönberg H, Björck E, Holck S, Nilbert M. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. *Gynecol Oncol* 2011; **121**: 462-465 [PMID: 21388660 DOI: 10.1016/j.ygyno.2011.02.010]

18 **Groth JV**, Prabhu S, Periakaruppan R, Ohlander S, Emmadi R, Kothari R. Coexistent Dedifferentiated Endometrioid Carcinoma of the Uterus and Adenocarcinoma of the Bladder in Lynch Syndrome: Case Report and Review of the Literature. *Appl Immunohistochem Mol Morphol* 2020; **28**: e26-e30 [PMID: 32167968 DOI: 10.1097/PAI.0000000000000553]

19 **Phelan A**, Lopez-Beltran A, Montironi R, Zhang S, Raspollini MR, Cheng M, Kaimakliotis HZ, Koch MO, Cheng L. Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. *Future Oncol* 2018; **14**: 277-290 [PMID: 29345160 DOI: 10.2217/fon-2017-0346]

20 **Ten Broeke SW**, Suerink M, Nielsen M. Response to Roberts *et al*. 2018: is breast cancer truly caused by MSH6 and PMS2 variants or is it simply due to a high prevalence of these variants in the population? *Genet Med* 2019; **21**: 256-257 [PMID: 29795439 DOI: 10.1038/s41436-018-0029-1]

21 **Tjalsma AS,** Wagner A, Dinjens WNM, Ewing-Graham PC, Alcalá LSM, de Groot MER, Hamoen KE, van Hof AC, Hofhuis W, Hofman LN, Hoogduin KJ, Kaijser J, Makkus ACF, Mol SJJ, Plaisier GM, Schelfhout K, Smedts HPM, Smit RA, Timmers PJ, Vencken PMLH, Visschers B, van der Wurff AAM, van Doorn HC. Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer. *Gynecol Oncol* 2021; **160**: 771-776 [PMID: 33419609 DOI: 10.1016/j.ygyno.2020.12.028]

22 **Stinton C**, Fraser H, Al-Khudairy L, Court R, Jordan M, Grammatopoulos D, Taylor-Phillips S. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy. *Gynecol Oncol* 2021; **160**: 148-160 [PMID: 33190932 DOI: 10.1016/j.ygyno.2020.10.003]

23 **Chen W**. Cancer statistics: updated cancer burden in China. *Chin J Cancer Res* 2015; **27**: 1 [PMID: 25717219 DOI: 10.3978/j.issn.1000-9604.2015.02.07]

24 **Cui MH**, Zhang XW, Yu T, Huang DW, Jia Y. PMS2 germline mutation c.1577delA (p.Asp526Alafs\*69)-induced Lynch syndrome-associated endometrial cancer: A case report. *Medicine (Baltimore)* 2019; **98**: e18279 [PMID: 31860975 DOI: 10.1097/MD.0000000000018279]

25 **Kumar A**, Paramasivam N, Bandapalli OR, Schlesner M, Chen T, Sijmons R, Dymerska D, Golebiewska K, Kuswik M, Lubinski J, Hemminki K, Försti A. A rare large duplication of MLH1 identified in Lynch syndrome. *Hered Cancer Clin Pract* 2021; **19**: 10 [PMID: 33468175 DOI: 10.1186/s13053-021-00167-0]

26 **Song XJ**, Liu ZL, Zeng R, Ye W, Liu CW. A meta-analysis of laparoscopic surgery *vs* conventional open surgery in the treatment of colorectal cancer. *Medicine (Baltimore)* 2019; **98**: e15347 [PMID: 31027112 DOI: 10.1097/MD.0000000000015347]

27 **Rohlin A**, Rambech E, Kvist A, Törngren T, Eiengård F, Lundstam U, Zagoras T, Gebre-Medhin S, Borg Å, Björk J, Nilbert M, Nordling M. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. *Fam Cancer* 2017; **16**: 195-203 [PMID: 27696107 DOI: 10.1007/s10689-016-9934-0]

28 **Jia S**, Zhang M, Sun Y, Yan H, Zhao F, Li Z, Ji J. A Chinese family affected by lynch syndrome caused by MLH1 mutation. *BMC Med Genet* 2018; **19**: 106 [PMID: 29929473 DOI: 10.1186/s12881-018-0605-x]

29 **Solassol J**, Larrieux M, Leclerc J, Ducros V, Corsini C, Chiésa J, Pujol P, Rey JM. Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndrome. *Hum Mutat* 2019; **40**: 716-720 [PMID: 30815977 DOI: 10.1002/humu.23725]

30 **Li Y**, Salo-Mullen E, Varghese A, Trottier M, Stadler ZK, Zhang L. Insertion of an Alu-like element in MLH1 intron 7 as a novel cause of Lynch syndrome. *Mol Genet Genomic Med* 2020; **8**: e1523 [PMID: 33058565 DOI: 10.1002/mgg3.1523]

31 **Hong J,** Kim H, Hong YS, Lee W, Lim S-B, Byeon J-S, Chun S, Min W-K. A Case of Lynch Syndrome with the Deletion of Multiple Exons of the MLH1 Gene, Detected by Next-Generation Sequencing. *J Lab Med Qual Assur* 2019; **41**: 220-224 [DOI: 10.15263/jlmqa.2019.41.4.220]

32 **Lagerstedt-Robinson K**, Rohlin A, Aravidis C, Melin B, Nordling M, Stenmark-Askmalm M, Lindblom A, Nilbert M. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. *Oncol Rep* 2016; **36**: 2823-2835 [PMID: 27601186 DOI: 10.3892/or.2016.5060]

33 **Singh S**, Resnick KE. Lynch Syndrome and Endometrial Cancer. *South Med J* 2017; **110**: 265-269 [PMID: 28376523 DOI: 10.14423/SMJ.0000000000000633]

34 **Wang Y**, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. *J Hematol Oncol* 2013; **6**: 22 [PMID: 23531335 DOI: 10.1186/1756-8722-6-22]

35 **Vasen HF**, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999; **116**: 1453-1456 [PMID: 10348829 DOI: 10.1016/s0016-5085(99)70510-x]

36 **Umar A**, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; **96**: 261-268 [PMID: 14970275 DOI: 10.1093/jnci/djh034]

37 **Buchanan DD**, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. *J Clin Oncol* 2014; **32**: 90-100 [PMID: 24323032 DOI: 10.1200/JCO.2013.51.2129]

38 **Provenzale D**, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, David DS, Early DS, Erwin D, Ford JM, Giardiello FM, Grady W, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Klapman JB, Larson DW, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Regenbogen SE, Samadder NJ, Shike M, Steinbach G, Weinberg D, Dwyer M, Darlow S. Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2016; **14**: 1010-1030 [PMID: 27496117 DOI: 10.6004/jnccn.2016.0108]

39 **Giardiello FM**, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. *Am J Gastroenterol* 2014; **109**: 1159-1179 [PMID: 25070057 DOI: 10.1038/ajg.2014.186]

40 **Goodfellow PJ**, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. *J Clin Oncol* 2015; **33**: 4301-4308 [PMID: 26552419 DOI: 10.1200/JCO.2015.63.9518]

41 **Kwon JS**, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. *J Clin Oncol* 2011; **29**: 2247-2252 [PMID: 21537049 DOI: 10.1200/JCO.2010.32.9979]

42 **Piñol V**, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. *JAMA* 2005; **293**: 1986-1994 [PMID: 15855432 DOI: 10.1001/jama.293.16.1986]

43 **Yoshihama T**, Hirasawa A, Sugano K, Yoshida T, Ushiama M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, Aoki D. Germline multigene panel testing revealed a *BRCA2* pathogenic variant in a patient with suspected Lynch syndrome. *Int Cancer Conf J* 2021; **10**: 6-10 [PMID: 33489693 DOI: 10.1007/s13691-020-00449-9]

44 **Kasela M,** Nyström M, Kansikas M. PMS2 expression decrease causes severe problems in mismatch repair. *Hum Mutat* 2019; **40**: 904-907 [PMID: 30946512 DOI: 10.1002/humu.23756]

45 Wang WM. Optimization strategy and screening status of colorectal cancer related Lynch syndrome with MLH1 deletion in Chinese population. *Annals of Oncology* 2018; **29**: viii176-viii177 [DOI: 10.1093/annonc/mdy281.073]

**Footnotes**

**Informed consent statement:** The approval for using the medical records for retrospective studies of this case study was provided by the Ethics Committee of the Second Hospital of Jilin University (2021. No.197). The patient signed an informed consent form.

**Conflict-of-interest statement:** The authors declare no conflict of interest for this article.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 18, 2021

**First decision:** January 25, 2022

**Article in press:**

**Specialty type:** Obstetrics and Gynecology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Dabravolski SA, Belarus; Yoshida H, Japan **A-Editor:** Yao QG, China **S-Editor:** Chang KL **L-Editor:** Wang TQ **P-Editor:**


**Figure Legends**




**Figure 1** **Preoperative abdominal magnetic resonance imaging**. A: Sagittal magnetic resonance imaging (MRI) showed an equal T1 and slightly longer T2 signal in the uterine cavity; B: Coronal MRI image; C: Axial MRI image. D: Enhanced MRI image showing that the lesions were inhomogeneous enhanced. The white arrowheads represent lesions. The tumor size was approximately 31 mm × 23 mm (B and C).



**Figure 2 Immunohistochemical images.** A: Loss of MLH1proteins was found in the tumor cells; B: Expression of MSH2 protein was detected in the tumor cells; C: Expression of MSH6 protein was detected in the tumor cells; D: Loss of PMS2protein was found in the tumor cells.



**Figure 3.** **Figures related to gene test results.** A deletion mutation of exon 6 was found in the *MLH1* gene.



**Figure 4** **Family pedigree.** The reconstructed pedigree demonstrates that the proband (II-9), her mother (I-1), her sisters (II-1, II-3, and II-5) and her brother (II-7), and her sister’s son (IV-4) experienced cancer. I-1 was diagnosed with colon cancer at 55 years and died at 70 years. II-1 and II-3, both at 60 years, suffered from colon cancer and endometrial cancer, respectively. II-5 experienced colon cancer at 40 years and endometrial cancer at 48 years. II-7 developed polyps of the colon at unknown age. III-4 had colon cancer at 25 years and died at 27 years. The arrow indicates the proband. Solid symbols reveal persons affected by malignancy. The symbol with a slash indicates a deceased individual with age at death. Circles indicate female family members, and squares suggest male family members.

**Table 1 Demographic characteristics**

|  |  |
| --- | --- |
| **Parameter** | **Outcome** |
| Sex | Female |
| Age (yr) | 57 |
| Sample type | Peripheral venous blood |
| Genes | *EPCAM*, *MLH1*, *MSH2*, *MSH6*, *PMS2*, *STK11*, *TP53*, *PTEN*, *MUTYH*, *BRCA1*, *MLH3* |
| Length of the target region (bp) | 49287 |
| Target area coverage | 100% |
| Average depth of target area (×) | 608.777386 |
| Average depth of target area > 30 × the proportion of sites | 99.78% |
| Detection range | Exon and its adjacent ± 20 bp intron region |

*EPCAM*: Epithelial cell adhesion molecule; *MLH1*: MutL homolog 1; *MSH2*: MutS homolog 2; *MSH6*: MutS homolog 6; *PMS2*: PMS1 homolog 2; *STK11*: Serine-Threonine Kinase 11; *TP53*: tumor protein 53; *PTEN*: Phosphatase and tensin homolog; *MUTYH*: Mut Y homolog; *BRCA1*: Breast cancer gene 1; *MLH3*: MutL homolog 3.

**Table 2 Gene detection of hereditary endometrial cancer**

|  |  |
| --- | --- |
| Parameter | Outcome |
| Diagnosis | Hereditary EC |
| Gene (NM number) | *MLH1* (NM\_000249.3) |
| Nucleotide changes | Exon 6 del |
| Amino acid changes | - |
| Gene subregion | Exon 6 |
| Heterozygous | Heterozygous mutation |
| Functional changes | Deletion |
| Genetic model | AD |
| Gene mutation type | Known pathogenic mutation |

EC: Endometrial cancer; AD: Autosomal dominant inheritance; *MLH1*: MutL homolog 1.

**Table 3 Variation information of exon region and its adjacent ± 20 bp intron region in hereditary endometrial cancer**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No. | Gene | Transcript | NV | AAC | GS | Heterozygous | Rs NO. | FC | MT |
| 1 | *MLH1* | NM\_000249.3 | EX6 DEL | - | EX6 | Het | - | Deletion | Kv |
| 2 | *MLH1* | NM\_000249.3 | c.1151T>A | p.Val384Asp | CDS12 | Het | rs63750447 | Missense | Bp |
| 3 | *MUTYH* | NM\_001128425.1 | c.74G>A | p.Gly25Asp | CDS2 | Het | rs75321043 | Missense | Uv |
| 4 | *MUTYH* | NM\_001128425.1 | c.53C>T | p.Pro18Leu | CDS2 | Het | rs79777494 | Missense | Uv |
| 5 | *MUTYH* | NM\_001128425.1 | c.36+11C>T | - | IN1 | Het | rs2275602 | Splice | Bp |
| 6 | *MUTYH* | NM\_001128425.1 | c.1014G>C | p.Gln338His | CDS12 | Het | rs3219489 | Missense | Bp |
| 7 | *BRCA1* | NM\_007294.3 | c.2612C>T | p.Pro871Leu | CDS9 | Het | rs799917 | Missense | Bp |
| 8 | *BRCA1* | NM\_007294.3 | c.4837A>G | p.Ser1613Gly | CDS14 | Het | rs1799966 | Missense | Bp |
| 9 | *BRCA1* | NM\_007294.3 | c.3548A>G | p.Lys1183Arg | CDS9 | Het | rs16942 | Missense | Bp |
| 10 | *BRCA1* | NM\_007294.3 | c.3113A>G | p.Glu1038Gly | CDS9 | Het | rs16941 | Missense | Bp |
| 11 | *EPCAM* | NM\_002354.2 | c.344T>C | p.Met115Thr | CDS3 | Het | rs1126497 | Missense | Bp |
| 12 | *MLH3* | NM\_014381.2 | c.2531C>T | p.Pro844Leu | CDS1 | Het | rs175080 | Missense | Bp |
| 13 | *MLH3* | NM\_014381.2 | c.2476A>G | p.Asn826Asp | CDS1 | Hom | rs175081 | Missense | Bp |
| 14 | *MSH2* | NM\_000251.2 | c.211+9C>G | - | IN1 | Het | rs2303426 | Splice | Bp |
| 15 | *MSH6* | NM\_000179.2 | c.3438+14A>C | - | IN5 | Hom | rs2020911 | Splice | Bp |
| 16 | *PMS2* | NM\_000535.6 | c.1408C>T | p.Pro470Ser | CDS11 | Het | rs1805321 | Missense | Bp |
| 17 | *PMS2* | NM\_000535.6 | c.2570G>C | p.Gly857Ala | CDS15 | Hom | rs1802683 | Missense | Bp |
| 18 | *PMS2* | NM\_000535.6 | c.706-4delT | - | IN6 | Het | rs6079473 | Splice | Bp |
| 19 | *PMS2* | NM\_000535.6 | c.59G>A | p.Arg20Gln | CDS2 | Het | rs10254120 | Missense | Bp |
| 20 | *PMS2* | NM\_000535.6 | c.1621A>G | p.Lys541Glu | CDS11 | Hom | rs2228006 | Missense | Bp |
| 21 | *PMS2* | NM\_000535.6 | c.705+17A>G | - | IN6 | Het | rs62456182 | Splice | Bp |
| 22 | *PMS2* | NM\_000535.6 | c.2007-4G>A | - | IN11 | Het | rs1805326 | Splice | Bp |
| 23 | *PMS2* | NM\_000535.6 | c.2007-7C>T | - | IN11 | Het | rs55954143 | Splice | Bp |
| 24 | *PTEN* | NM\_000314.6 | c.802-3dupT | - | IN7 | Het | rs762344516 | Splice | Bp |
| 25 | *TP53* | NM\_000546.5 | c.215C>G | p.Pro72Arg | CDS3 | Het | rs1042522 | Missense | Bp |

EC: Endometrial cancer; NV: Nucleotide variation; AAC: Amino acid changes; GS: Gene subregion; Rs NO.: rs number; FC: Functional changes; MT: Mutation types; Kv: Known variation; Uv: Unknown variation; Bp: Benign polymorphism; Het: Heterozygous; Hom: Homozygous.